Moreover, evidence suggests that ANXA1 may also act as an upstream activator of NF-κB signaling, which activates nuclear factor-erythroid 2-related factor 3 (Nrf3), leading to decreased apoptosis and an increased resistance of CRC cells to 5-FU [25,74,190]. The gene discussed is NFKB1; the disease is colorectal carcinoma.